TrialClinical pharmacokinetics2026

Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.

Mette J F Nielsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.